ANKRD1 is a stress-responsive transcriptional regulator with dual subcellular localization and context-dependent functions. In the nucleus, ANKRD1 acts as a transcriptional cofactor that can be activated by IL11/STAT3 signaling 1 and nuclear AGO2 2, promoting pathological cardiac remodeling and MYH7 activation in heart failure 2. ANKRD1 also functions as a mesenchymal-specific driver of cancer-associated fibroblast (CAF) activation by bridging androgen receptor loss to AP-1 transcription factor binding, controlling myofibroblast gene expression programs 3. In renal ischemia-reperfusion injury, ANKRD1 exacerbates damage by promoting TRIM25-mediated K63-linked ubiquitination and degradation of ACSL3, amplifying ferroptosis and lipid peroxidation 4. ANKRD1 shows sustained upregulation during progression from acute to chr10 kidney disease, suggesting biomarker potential 5. Notably, ANKRD1 exhibits tumor-suppressive functions when p53-dependent: it induces p53 and pro-apoptotic genes (BAX, CDKN1A) while destabilizing MDM2, and is epigenetically silenced in cancer 6. Cytosolic ANKRD1 appears cardioprotective 2, indicating its subcellular compartmentalization critically determines biological outcomes across cardiac, renal, and cancer contexts.